Introduction:
The market for biosimilars poultry treatments in China is rapidly growing, reflecting the overall trend of increasing demand for pharmaceutical products in the country. According to recent data, the biosimilars market in China is expected to reach $5 billion by 2026, with a compound annual growth rate of 25%. This market report will highlight the top 10 biosimilars poultry treatments in China in 2026.
Top 10 Biosimilars Poultry Treatments in China 2026:
1. Avian Influenza Vaccine by Sinovac Biotech
Sinovac Biotech’s Avian Influenza Vaccine holds the largest market share in China, with an estimated production volume of 100 million doses per year. It is widely used by poultry farmers across the country to prevent outbreaks of avian influenza.
2. Newcastle Disease Vaccine by Harbin Veterinary Research Institute
The Newcastle Disease Vaccine developed by Harbin Veterinary Research Institute is a key player in the poultry treatments market in China. With a market share of 30%, this vaccine is essential for protecting poultry from the deadly Newcastle Disease.
3. Infectious Bronchitis Vaccine by Merial
Merial’s Infectious Bronchitis Vaccine is a popular choice among poultry farmers in China, with an estimated market share of 20%. This vaccine helps prevent respiratory diseases in chickens, improving overall poultry health.
4. Salmonella Vaccine by Ceva Animal Health
Ceva Animal Health’s Salmonella Vaccine is gaining traction in the Chinese market, with a production volume of 50 million doses per year. This vaccine is crucial for reducing the prevalence of Salmonella contamination in poultry products.
5. Eimeria Vaccine by HIPRA
HIPRA’s Eimeria Vaccine is a leading product for controlling coccidiosis in poultry, with an estimated market share of 15%. This vaccine plays a vital role in maintaining the health and productivity of poultry flocks in China.
6. Fowl Cholera Vaccine by Zoetis
Zoetis’ Fowl Cholera Vaccine is a key player in the poultry treatments market in China, with a production volume of 40 million doses per year. This vaccine is essential for preventing outbreaks of fowl cholera in poultry farms.
7. Marek’s Disease Vaccine by MSD Animal Health
MSD Animal Health’s Marek’s Disease Vaccine is a top choice for protecting poultry from Marek’s Disease, with an estimated market share of 10%. This vaccine is crucial for maintaining the health and productivity of poultry flocks in China.
8. Infectious Bursal Disease Vaccine by Boehringer Ingelheim
Boehringer Ingelheim’s Infectious Bursal Disease Vaccine is a leading product for preventing Gumboro disease in poultry, with a production volume of 30 million doses per year. This vaccine plays a significant role in ensuring the health and welfare of poultry in China.
9. Avian Leukosis Vaccine by Elanco
Elanco’s Avian Leukosis Vaccine is a popular choice among poultry farmers in China, with an estimated market share of 12%. This vaccine helps prevent avian leukosis, a viral disease that can impact the productivity of poultry flocks.
10. Coccidiosis Vaccine by Phibro Animal Health
Phibro Animal Health’s Coccidiosis Vaccine is a key player in the poultry treatments market in China, with a production volume of 25 million doses per year. This vaccine is essential for controlling coccidiosis, a common parasitic disease in poultry.
Insights:
The market for biosimilars poultry treatments in China is expected to continue growing at a rapid pace, driven by increasing demand for safe and effective vaccines in the poultry industry. With a projected market size of $5 billion by 2026, pharmaceutical companies are investing heavily in research and development to meet the needs of poultry farmers in China. As the government continues to focus on food safety and security, the demand for high-quality poultry treatments is expected to remain strong in the coming years. By leveraging innovative technologies and strategic partnerships, companies can capitalize on the opportunities presented by the growing biosimilars market in China.
Related Analysis: View Previous Industry Report
